Delcath Systems, Inc. (NASDAQ:DCTH) Given Consensus Rating of "Moderate Buy" by Brokerages

Key Points

• Delcath Systems has a “Moderate Buy” consensus rating from seven analysts: five rate it a buy, one a strong buy, and one a sell. The average 12-month price target is $23.17.
• Recent analyst actions were largely positive, including BTIG raising its target to $21 and HC Wainwright increasing its target to $32, while Zacks upgraded the stock to “strong buy.”
• Delcath exceeded quarterly expectations, reporting EPS of $0.07 versus a forecasted loss of $0.09 and revenue of $29.13 million versus estimates of $26.25 million. Institutional investors own 61.12% of the company.

Delcath Systems, Inc. (NASDAQ:DCTH - Get Free Report) has earned an average rating of "Moderate Buy" from the seven brokerages that are presently covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, five have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month target price among brokerages that have updated their coverage on the stock in the last year is $23.1667.

A number of brokerages have issued reports on DCTH. Weiss Ratings lowered Delcath Systems from a "sell (d+)" rating to a "sell (d)" rating in a research report on Friday. BTIG Research increased their target price on Delcath Systems from $17.00 to $21.00 and gave the stock a "buy" rating in a research note on Thursday, August 6th. Wall Street Zen upgraded Delcath Systems from a "hold" rating to a "buy" rating in a report on Saturday, August 8th. HC Wainwright reaffirmed a "buy" rating and issued a $32.00 target price (up from $30.00) on shares of Delcath Systems in a research report on Friday, August 7th. Finally, Zacks Research raised Delcath Systems from a "hold" rating to a "strong-buy" rating in a research report on Monday, August 10th.

Delcath Systems Price Performance

Shares of DCTH stock opened at $17.14 on Monday. Delcath Systems has a 1-year low of $8.12 and a 1-year high of $17.42. The firm has a market cap of $594.76 million, a PE ratio of 1,715.72 and a beta of 0.52. The company has a 50-day moving average of $13.55 and a two-hundred day moving average of $11.35.

Delcath Systems (NASDAQ:DCTH - Get Free Report) last issued its quarterly earnings data on Thursday, August 6th. The company reported $0.07 EPS for the quarter, topping the consensus estimate of ($0.09) by $0.16. The firm had revenue of $29.13 million for the quarter, compared to analyst estimates of $26.25 million. Delcath Systems had a net margin of 0.56% and a return on equity of 0.46%. Sell-side analysts anticipate that Delcath Systems will post -0.17 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. California State Teachers Retirement System purchased a new stake in Delcath Systems during the 2nd quarter worth approximately $26,000. Russell Investments Group Ltd. purchased a new position in Delcath Systems in the 3rd quarter valued at approximately $29,000. Tower Research Capital LLC TRC acquired a new position in shares of Delcath Systems in the second quarter worth $40,000. Legal & General Group Plc acquired a new position in shares of Delcath Systems in the second quarter worth $46,000. Finally, The Manufacturers Life Insurance Company purchased a new stake in shares of Delcath Systems during the second quarter worth $151,000. Institutional investors and hedge funds own 61.12% of the company's stock.

About Delcath Systems

Delcath Systems, Inc is a specialty pharmaceutical and medical technology company focused on the development and commercialization of its proprietary Hepatic CHEMOSAT® Delivery System, designed to deliver high-dose chemotherapeutic agents directly to the liver while minimizing systemic exposure. The company's core technology performs isolated hepatic perfusion, enabling oncologists to administer concentrated melphalan to patients with primary and metastatic liver tumors, including those arising from ocular melanoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source